Ozempic vs Mounjaro
Brand name comparison of two leading GLP-1 medications for type 2 diabetes management.
Last updated: January 28, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
Semaglutide
Dossier overview
Tirzepatide
Dossier overview
Overview
Ozempic and Mounjaro are brand names for two of the most widely prescribed GLP-1-based medications for type 2 diabetes. Ozempic contains semaglutide (a GLP-1 receptor agonist), while Mounjaro contains tirzepatide (a dual GLP-1/GIP receptor agonist).
Both are FDA-approved for type 2 diabetes, administered via weekly subcutaneous injection, and have demonstrated significant efficacy in clinical trials.
Key Facts
| Aspect | Ozempic | Mounjaro |
|---|---|---|
| Generic Name | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Eli Lilly |
| FDA Approval | 2017 (T2D) | 2022 (T2D) |
| Mechanism | GLP-1 agonist | Dual GLP-1/GIP agonist |
Mechanism Comparison
| Aspect | Ozempic | Mounjaro |
|---|---|---|
| Receptor Targets | GLP-1 only | GLP-1 + GIP |
| Action | Single agonist | Dual agonist |
| Insulin Release | Enhanced | Enhanced (two pathways) |
| Glucagon Suppression | Yes | Yes |
How They Work
Ozempic (Semaglutide):
- Activates GLP-1 receptors
- Increases glucose-dependent insulin secretion
- Slows gastric emptying
- Reduces appetite via central mechanisms
Mounjaro (Tirzepatide):
- Activates both GLP-1 and GIP receptors
- May provide synergistic metabolic effects
- Enhanced insulin response through dual signaling
- Potentially greater beta-cell benefits
Clinical Trial Evidence
Efficacy for Type 2 Diabetes
| Trial Program | Ozempic (SUSTAIN) | Mounjaro (SURPASS) |
|---|---|---|
| A1C Reduction | 1.0-1.8% | 1.8-2.4% |
| Weight Loss | 4-6 kg | 5-12 kg |
| Participants | 8,000+ across program | 7,000+ across program |
Head-to-Head Data
The SURPASS-2 trial compared tirzepatide to semaglutide 1mg:
- Tirzepatide showed greater A1C reductions at all dose levels
- Tirzepatide showed greater weight loss
- Both had similar GI side effect profiles
Safety Comparison
Common Side Effects
| Side Effect | Ozempic | Mounjaro |
|---|---|---|
| Nausea | Common | Common |
| Diarrhea | Common | Common |
| Vomiting | Common | Common |
| Constipation | Less common | Common |
| Injection site reactions | Rare | Rare |
Warnings
Both medications carry similar warnings:
- Thyroid C-cell tumors: Boxed warning (rodent studies)
- Pancreatitis: Risk consideration
- Diabetic retinopathy: Monitor in patients with history
- Hypoglycemia: When used with insulin/sulfonylureas
- Acute kidney injury: Dehydration risk with GI effects
Key Differences
| Factor | Ozempic | Mounjaro |
|---|---|---|
| Mechanism | Single receptor | Dual receptor |
| Time on Market | Longer (2017) | Newer (2022) |
| Trial Data Volume | More long-term data | Less long-term data |
| Cardiovascular Data | SELECT trial completed | CV outcomes trial ongoing |
Regulatory Status
| Aspect | Ozempic | Mounjaro |
|---|---|---|
| T2D Approval | FDA approved (2017) | FDA approved (2022) |
| Weight Loss | Wegovy (separate brand) | Zepbound (separate brand) |
| Cardiovascular | CV risk reduction claim | Pending |
Summary
Both Ozempic and Mounjaro are effective, FDA-approved medications for type 2 diabetes:
- Ozempic: Established GLP-1 agonist with extensive real-world data and cardiovascular outcomes evidence
- Mounjaro: Newer dual agonist with potentially greater efficacy for glycemic control and weight loss in trials
The choice between them involves clinical considerations including:
- Individual response to therapy
- Specific metabolic goals
- Insurance coverage and access
- Cardiovascular risk profile
This comparison is for educational purposes only. Medication decisions should be made with a healthcare provider.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.